Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Apr 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.
- 15 Jan 2018 New trial record